Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GALR3 | O60755 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162979 | 0.89 | HTT (0.66) | HTTMEN1KMT2AGALR3SMN1; SMN2 | |
| SCHEMBL27485649 | 0.84 | ALDH1A1 (0.49) | HTTMEN1KMT2AGALR3SMN1; SMN2 | |
| SCHEMBL3600387 | 0.82 | ALDH1A1 (0.63) | HTTMEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL21653949 | 0.82 | ALDH1A1 (0.58) | HTTMEN1KMT2AGALR3SMN1; SMN2 | |
| SCHEMBL15325677 | 0.81 | ALDH1A1 (0.46) | HTTMEN1KMT2AGALR3SMN1; SMN2 | |
| SCHEMBL12824753 | 0.81 | HTT (0.56) | HTTMEN1KMT2AGALR3SMN1; SMN2 | |
| SCHEMBL19130787 | 0.80 | MEN1 (0.82) | HTTMEN1KMT2AGALR3SMN1; SMN2 | |
| SCHEMBL2119829 | 0.77 | ALDH1A1 (0.62) | HTTALDH1A1CYP3A4TDP1TSHR | |
| SCHEMBL12825156 | 0.77 | XDH (0.60) | HTTMEN1KMT2AGALR3SMN1; SMN2 | |
| SCHEMBL698724 | 0.77 | HTT (0.56) | HTTMEN1KMT2AGALR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070044254-A1 | Novel 2,6-disubstituted primary para-phenylenediamines and process for their use in the oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2007-03-01 | — | — | US | disclosed |
| EP-1757579-A1 | Primary 2,6-disubstituted para-phenylenediamines and their uses for dyeing keratin fibres | L'Oréal (FR) | 2007-02-28 | — | — | EP | disclosed |
| EP-1757579-A1 | Primary 2,6-disubstituted para-phenylenediamines and their uses for dyeing keratin fibres | L'Oréal (FR) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070044254-A1 | Novel 2,6-disubstituted primary para-phenylenediamines and process for their use in the oxidation dyeing of keratin fibers | KRT18, DSP, CDC73 | HTT 4243/4885MEN1 4466/4885KMT2A 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.